ClinicalTrials.Veeva

Menu

Xiangtong TM Full Degradation Sinus Drug Stent System Prospective, Open, Single-center, Randomized Controlled Clinical Trial

N

Nanjing Medical University

Status

Not yet enrolling

Conditions

Chronic Rhinosinusitis (CRS)

Treatments

Device: Xiangtong TM full degradation sinus drug stent system
Device: nasopore

Study type

Interventional

Funder types

Other

Identifiers

NCT06669130
2024-SR-350

Details and patient eligibility

About

Xiangtong® Fully Degradable Sinus Drug Stent System is a high-tech medical device independently developed by Puyi Bio, specially designed for patients with chronic rhinosinusitis (CRS) undergoing endoscopic sinus surgery (ESS).The product is implanted into the target site during and after surgery, which not only supports the separation of the wound and fixes the repaired mucosal flap, but also controls edema, prevents adhesions, maintains smooth drainage, and sustains the target site to fight against inflammation and promotes healing by means of slow-release hormones.

Enrollment

50 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Subjects are 18-65 years of age, male or non-pregnant female. The subject/legally authorized representative understands the purpose and procedures of the trial and voluntarily signs an informed consent form.

Subjects must meet the diagnostic guidelines for chronic rhinosinusitis, have a confirmed diagnosis of bilateral chronic rhinosinusitis, and have a CT scan confirming bilateral Lund-Mackay scores >6 (CT scan within 3 months prior to surgery is valid).

  • Female subjects who are not breastfeeding at the time of the screening visit and who do not plan to breastfeed or become pregnant for up to one year after the starting point.
  • Subject has not participated in another clinical trial in the previous 3 months and agrees not to participate in another clinical trial until the endpoints of this trial have been met.

Exclusion criteria

  • Subject has a known allergic reaction or contraindication to the device material and its degradation products (mometasone acid, levulinic acid, racemic polylactic acid, propyl lactate, lactic acid).
  • The subject is on long-term oral hormonal medications.
  • The subject is receiving immunosuppressive therapy or has a known immunosuppressive or autoimmune disease: the subject has diabetes mellitus.
  • The subject has or has had glaucoma or high intraocular pressure.
  • The subject has cataracts.
  • The subject has an artificial eye.
  • Acute bacterial sinusitis and acute fungal sinusitis.
  • Subject has a life expectancy of less than 12 months.
  • Subject has participated in a clinical trial of another drug or device that did not meet the primary study endpoint: Subject is unable or unwilling to participate in this trial.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

50 participants in 2 patient groups, including a placebo group

Xiangtong TM full degradation sinus drug stent system
Experimental group
Treatment:
Device: Xiangtong TM full degradation sinus drug stent system
nasopore
Placebo Comparator group
Treatment:
Device: nasopore

Trial contacts and locations

0

Loading...

Central trial contact

Cheng Lei

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems